Suvarna Garge (Editor)

Rinat Neuroscience Corporation

Updated on
Edit
Like
Comment
Share on FacebookTweet on TwitterShare on LinkedInShare on Reddit

Rinat Neuroscience Corporation was a privately held biotechnology company that discovered and developed antibody-based drugs including:

  • Tanezumab (codenamed RN624)., a monoclonal antibody against nerve growth factor for the treatment of pain
  • Ponezumab (codenamed RN1219), a monoclonal antibody against Beta amyloid for the treatment of Alzheimer's disease
  • TEV-48125 (codenamed RN307 before it became LBR-101), a monoclonal antibody against Calcitonin gene-related peptide for the treatment of migraines
  • Bococizumab (codenamed RN316), a monoclonal antibody against PCSK9 designed to reduce LDL cholesterol

    • Rinat was founded in 2001 by Arnon Rosenthal and Patrick Lynn, following a broad licensing agreement with Genentech, and was acquired by Pfizer in 2006 for approximately $500M. Rinat currently operates as an independent biotechnology unit within Pfizer's Worldwide R&D group in South San Francisco

    References

    Rinat Neuroscience Corporation Wikipedia
    (Text) CC BY-SA


    Similar Topics